{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.83","upperLimit":"16.82","value":"14.26"},{"groupId":"OG001","lowerLimit":"13.96","upperLimit":"22.93","value":"17.51"},{"groupId":"OG002","lowerLimit":"10.15","upperLimit":"15.90","value":"12.68"},{"groupId":"OG003","lowerLimit":"12.71","upperLimit":"18.96","value":"16.20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"115"},{"groupId":"OG002","value":"111"},{"groupId":"OG003","value":"112"}],"units":"Participants"}],"description":"The observed length of life from randomization into the study to death or the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Paclitaxel 135 mg/m2 IV over 24 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 1 Cycles repeated q21 days to progression/toxicity","id":"OG000","title":"Arm I (Paclitaxel and Cisplatin)"},{"description":"Paclitaxel 135 mg/m2 IV over 24 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 Bevacizumab 15 mg/kg IV day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 Bevacizumab 15 mg/kg IV day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 1 Bevacizumab 15 mg/kg IV day 1 Cycles repeated q21 days to progression/toxicity","id":"OG001","title":"Arm II (Paclitaxel, Cisplatin, Bevacizumab)"},{"description":"Paclitaxel 175 mg/m2 over 3 hrs on day 1 Topotecan 0.75 mg/m2 over 30 mins days 1-3 Cycles repeated q21 days to progression/toxicity","id":"OG002","title":"Arm III (Topotecan Hydrochloride and Paclitaxel)"},{"description":"Paclitaxel 175 mg/m2 over 3 hrs on day 1 Topotecan 0.75 mg/m2 over 30 mins days 1-3 Bevacizumab 15 mg/kg IV day 1 Cycles repeated q21 days to progression/toxicity","id":"OG003","title":"Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab)"}],"paramType":"MEDIAN","populationDescription":"All randomized patients.","reportingStatus":"POSTED","timeFrame":"From entry into the study to death or the date of last contact, assessed up to 5 years","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"months"}